Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone617-807-6600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.12 million
Profitability
Miscellaneous
Employees101
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its earnings results on Tuesday, August, 6th. The specialty pharmaceutical company reported ($1.02) earnings per share for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. The specialty pharmaceutical company earned $2.05 million during the quarter, compared to the consensus estimate of $1.86 million. Paratek Pharmaceuticals had a negative net margin of 597.22% and a negative return on equity of 459.96%. View Paratek Pharmaceuticals' Earnings History.
When is Paratek Pharmaceuticals' next earnings date?
What price target have analysts set for PRTK?
6 analysts have issued 12 month price objectives for Paratek Pharmaceuticals' shares. Their predictions range from $12.00 to $26.00. On average, they expect Paratek Pharmaceuticals' share price to reach $19.3333 in the next year. This suggests a possible upside of 359.2% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.
What is the consensus analysts' recommendation for Paratek Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.
What are Wall Street analysts saying about Paratek Pharmaceuticals stock?
Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (8/9/2019)
- 2. HC Wainwright analysts commented, "We view the promotion of Dr. Loh as particularly well-deserved and quite likely to be broadly well-received by investors and other constituents. Affirm Buy." (6/26/2019)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
Media stories about PRTK stock have trended positive this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Paratek Pharmaceuticals.
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include DiaMedica Therapeutics (DMCAF), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), Kiniksa Pharmaceuticals (KNSA), Aurinia Pharmaceuticals (AUPH), Advanz Pharma (CXRXF), Karuna Therapeutics (KRTX), Endo International (ENDP), Revance Therapeutics (RVNC), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Aptorum Group (APM), Syros Pharmaceuticals (SYRS), Atreca (BCEL) and Sinovac Biotech (SVA).
What other stocks do shareholders of Paratek Pharmaceuticals own?
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 61)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 60)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 57)
- Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 52)
- Mr. Douglas W. Pagán, Consultant (Age 47)
Who are Paratek Pharmaceuticals' major shareholders?
Paratek Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.85%), Vanguard Group Inc. (4.93%), Roumell Asset Management LLC (2.09%), General American Investors Co. Inc. (1.45%), Northern Trust Corp (1.27%) and JPMorgan Chase & Co. (0.86%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Robert S Radie, Thomas John Dietz and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Which major investors are selling Paratek Pharmaceuticals stock?
PRTK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Wells Fargo & Company MN, BlackRock Inc., Bank of New York Mellon Corp, Wedbush Securities Inc., JPMorgan Chase & Co. and Morgan Stanley. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Jeffrey Stein, Michael Bigham, Thomas John Dietz and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.
Which major investors are buying Paratek Pharmaceuticals stock?
PRTK stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Parametric Portfolio Associates LLC, Trellus Management Company LLC, A.R.T. Advisors LLC, Roumell Asset Management LLC, Alambic Investment Management L.P., Charles Schwab Investment Management Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $4.21.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $136.97 million and generates $17.12 million in revenue each year. The specialty pharmaceutical company earns $-112,360,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. Paratek Pharmaceuticals employs 101 workers across the globe.View Additional Information About Paratek Pharmaceuticals.
What is Paratek Pharmaceuticals' official website?
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
